BLOOD LIPOPROTEIN SPECTRUM AND THE LEVEL OF VASOACTIVE ENDOTHELIAL FACTORS IN CHILDREN WITH ARTERIAL HYPOTENSION

2021 ◽  
pp. 106-114
Author(s):  
A. V. Sikorski ◽  
◽  
I. I. Savanovich ◽  
T. A. Sikorskaya ◽  
V. A. Pereverzev ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Low Density Lipoprotein ◽  
Lipoprotein Metabolism ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Arterial Hypotension ◽  
High Concentration ◽  
Transporter Protein ◽  
Endothelial Factors ◽  
Characteristic Features

The article presents the data on the characteristic features of lipoprotein metabolism and the level of vasoactive endothelial factors in children with primary and symptomatic arterial hypotension. Dyslipidemia in the first group of patients is characterized by an increase in low-density lipoprotein cholesterol, apolipoprotein B100, the atherogenicity coefficient, the ApoLP atherogenicity index, a high concentration of nitric oxide in case of low levels of high-density lipoprotein cholesterol and ApoLP A1. In children with chronic gastroduodenal pathology and symptomatic arterial hypotension, the above disorders of lipoprotein metabolism and endothelial function are accompanied by an increased content of total cholesterol and bradykinin. These data suggest that in children with primary and symptomatic arterial hypotension, conditions for the formation of the initial atherosclerotic process are created due to the predominance of the pro-atherogenic Apo B100 transporter protein over the anti-atherogenic Apo A1, as well as due to a significant increase in nitric oxide and endothelial dysfunction.

scholarly journals ANGPTL3 Levels in Healthy and Mild Preeclamptic Pregnant Women

2021 ◽  
Vol 5 (Supplement_1) ◽  
pp. A747-A747
Author(s):  
Maria F Garces ◽  
Roberto Franco - Vega ◽  
Luis M Maldonado - Acosta ◽  
Andres Castro - Pinzón ◽  
Javier Eslava-Schmalbach ◽  
...  
Keyword(s):  
Pregnant Women ◽  
Low Density Lipoprotein ◽  
Lipoprotein Metabolism ◽  
Density Lipoprotein ◽  
Study Groups ◽  
Normal Pregnancy ◽  
Lipoprotein Cholesterol ◽  
Fed State ◽  
The Third ◽  
Cholesterol Levels

Abstract Introduction: Throughout normal pregnancy, different metabolic and hormonal adaptations are presented, among others, significant modifications in the profile of lipids and lipoprotein metabolism. On the other hands, Angiopoietin-like protein 3 (ANGPTL3) are involved in the regulation of triglyceride metabolism in the fed state by inhibiting the enzyme lipoprotein lipase in oxidative tissues. Objective: Thus, the objective of this study was to determine the profile of serum ANGPTL3 levels during three periods of gestation and three months after delivery. Design, setting and Participants: Serum ANGPTL3 levels were analyzed by ELISA, throughout pregnancy in a case-control study nested within a longitudinal prospective cohort of healthy pregnant (n = 52) and mild preeclamptic women (n = 20), women in the third month postpartum (n = 20) and healthy non-pregnant women (n = 20). The results obtained were correlated with biochemical, hormonal, and anthropometric variables. Results: A significant reduction in ANGPTL3 levels was observed from the first to the third trimesters of pregnancy in healthy and preeclamptic pregnant women when compared with healthy non-pregnant and postpartum women (p<0.01). There were no significant differences in serum ANGPTL3 levels between normal and preeclamptic women. Serum ANGPTL3 levels were positively correlated with triglyceride, very-low-density lipoprotein cholesterol, and total cholesterol levels in healthy non-pregnant (p<0.05); whereas there were no significant correlations between ANGPTL3 with the same variables in healthy and preeclamptic pregnant women. Besides, there were no significant correlations between serum ANGPTL3 with body mass index, high-density lipoprotein cholesterol, glucose, insulin, leptin or HOMA-IR in the study groups described above. Conclusions: The results of the present study show for the first time that ANGPTL3 could be playing a fundamental role in the homeostasis of lipid metabolism throughout gestation. Thus, low levels of ANGPTL3 during pregnancy might favor the accumulation of lipid in oxidative tissues as a deposit of maternal energy source, while preserving glucose and amino acids for the fetus.

scholarly journals Angiopoietin-Like Protein 3 (ANGPTL3) Modulates Lipoprotein Metabolism and Dyslipidemia

2021 ◽  
Vol 22 (14) ◽  
pp. 7310
Author(s):  
Pei-Yi Chen ◽  
Wan-Yun Gao ◽  
Je-Wen Liou ◽  
Ching-Yen Lin ◽  
Ming-Jiuan Wu ◽  
...  
Keyword(s):  
Clinical Studies ◽  
Plasma Levels ◽  
Low Density Lipoprotein ◽  
Lipoprotein Metabolism ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Lipid Lowering ◽  
Lipid Lowering Therapy ◽  
Loss Of Function ◽  
Potential Strategy

Dyslipidemia is characterized by increasing plasma levels of low-density lipoprotein-cholesterol (LDL-C), triglycerides (TGs) and TG-rich lipoproteins (TGRLs) and is a major risk factor for the development of atherosclerotic cardiovascular disorders (ASCVDs). It is important to understand the metabolic mechanisms underlying dyslipidemia to develop effective strategies against ASCVDs. Angiopoietin-like 3 (ANGPTL3), a member of the angiopoietin-like protein family exclusively synthesized in the liver, has been demonstrated to be a critical regulator of lipoprotein metabolism to inhibit lipoprotein lipase (LPL) activity. Genetic, biochemical, and clinical studies in animals and humans have shown that loss of function, inactivation, or downregulated expression of ANGPTL3 is associated with an obvious reduction in plasma levels of TGs, LDL-C, and high-density lipoprotein-cholesterol (HDL-C), atherosclerotic lesions, and the risk of cardiovascular events. Therefore, ANGPTL3 is considered an alternative target for lipid-lowering therapy. Emerging studies have focused on ANGPTL3 inhibition via antisense oligonucleotides (ASOs) and monoclonal antibody-based therapies, which have been carried out in mouse or monkey models and in human clinical studies for the management of dyslipidemia and ASCVDs. This review will summarize the current literature on the important role of ANGPTL3 in controlling lipoprotein metabolism and dyslipidemia, with an emphasis on anti-ANGPTL3 therapies as a potential strategy for the treatment of dyslipidemia and ASCVDs.

Understanding lipoproteins as transporters of cholesterol and other lipids

2004 ◽  
Vol 28 (3) ◽  
pp. 105-106 ◽  
Author(s):  
Kyle D. Biggerstaff ◽  
Joshua S. Wooten
Keyword(s):  
Physiological Function ◽  
Particle Density ◽  
Low Density Lipoprotein ◽  
Critical Role ◽  
Lipoprotein Metabolism ◽  
Density Lipoprotein ◽  
Protein Composition ◽  
Lipoprotein Cholesterol ◽  
Low Density Lipoprotein Cholesterol ◽  
Lipid Transporters

A clear picture of lipoprotein metabolism is essential for understanding the pathophysiology of atherosclerosis. Many students are taught that low-density lipoprotein-cholesterol is “bad” and high-density lipoprotein-cholesterol is “good.” This misconception leads to students thinking that lipoproteins are types of cholesterol rather than transporters of lipid. Describing lipoproteins as particles that are composed of lipid and protein and illustrating the variation in particle density that is determined by the constantly changing lipid and protein composition clarifies the metabolic pathway and physiological function of lipoproteins as lipid transporters. Such a description will also suggest the critical role played by apolipoproteins in lipid transport. The clarification of lipoproteins as particles that change density will help students understand the nomenclature used to classify lipoproteins as well.

scholarly journals Mechanisms of Dyslipoproteinemias in Systemic Lupus Erythematosus

2006 ◽  
Vol 13 (2-4) ◽  
pp. 203-208 ◽  
Author(s):  
Eduardo F. Borba ◽  
Jozelio F. Carvalho ◽  
Eloísa Bonfá
Keyword(s):  
Lupus Erythematosus ◽  
Foam Cell ◽  
Low Density Lipoprotein ◽  
Cell Formation ◽  
Lipoprotein Metabolism ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Ldl Oxidation ◽  
Foam Cell Formation ◽  
Key Enzyme

Autoimmunity and inflammation are associated with marked changes in lipid and lipoprotein metabolism in SLE. Autoantibodies and cytokines are able to modulate lipoprotein lipase (LPL) activity, a key enzyme in lipid metabolism, with a consequent “lupus pattern” of dyslipoproteinemia characterized by elevated levels of very low-density lipoprotein cholesterol (VLDL) and triglycerides (TG) and lower high-density lipoprotein cholesterol (HDL) levels. This pattern favors an enhanced LDL oxidation with a subsequent deleterious foam cell formation. Autoantibodies and immunocomplexes may aggravate this oxidative injury by inducing accumulation and deposition of oxLDL in endothelial cells. Drugs and associated diseases usually magnify the close interaction of these factors and further promote the proatherogenic environment of this disease.

Associations of theNOS3rs1799983 polymorphism with circulating nitric oxide and lipid levels: a systematic review and meta-analysis

2019 ◽  
Vol 95 (1125) ◽  
pp. 361-371 ◽  
Author(s):  
Zhi Luo ◽  
Aimei Jia ◽  
Zhan Lu ◽  
Irfan Muhammad ◽  
Adebayo Adenrele ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Systematic Review ◽  
Plasma Levels ◽  
Meta Analysis ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Outcome Variable ◽  
Lipid Levels ◽  
Association Analyses

BackgroundCirculating nitric oxide (NO) and lipid levels are closely associated with coronary artery disease (CAD). It is unclear whether the rs1799983 polymorphism in endothelial nitric oxide synthase (NOS3) gene is associated with plasma levels of NO and lipids. This systematic review and meta-analysis (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) aimed to clarify the relationships between the rs1799983 polymorphism and plasma levels of NO and lipids.MethodsSixteen studies (2702 subjects) and 59 studies (14 148 subjects) were identified for the association analyses for NO and lipids, respectively. Mean difference (MD) and 95% CI were used to estimate the effects of the rs1799983 polymorphism on plasma NO and lipid levels. The primary outcome variable was NO, and the secondary outcomes included triglycerides, total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C).ResultsCarriers of the T allele had lower levels of NO (MD −0.27 μmol/L, 95% CI −0.42 to −0.12 μmol/L, p<0.001) and HDL-C (MD −0.07 mmol/L, 95% CI −0.14 to −0.00 mmol/L, p=0.04), and higher levels of TC (MD 0.13 mmol/L, 95% CI 0.06 to 0.20 mmol/L, p<0.001) and LDL-C (MD 0.14 mmol/L, 95% CI 0.05 to 0.22 mmol/L, p=0.002) than the non-carriers. Triglyceride levels were comparable between the genotypes.ConclusionThe association between theNOS3rs1799983 polymorphism and CAD may be partly mediated by abnormal NO and lipid levels caused by the T allele.

Growth hormone and thyroxine affect lipoprotein metabolism in hypothyroid and hypophysectomized rats

1990 ◽  
Vol 125 (3) ◽  
pp. 403-407 ◽  
Author(s):  
N. Hoogerbrugge-v.d.Linden ◽  
H. Jansen ◽  
N. M. H. Wouters ◽  
J. C. Birkenhäger
Keyword(s):  
Replacement Therapy ◽  
Low Density Lipoprotein ◽  
Lipoprotein Metabolism ◽  
Density Lipoprotein ◽  
Primary Hypothyroidism ◽  
Lipoprotein Cholesterol ◽  
Serum Lipoproteins ◽  
Gh Treatment ◽  
Secondary Hypothyroidism ◽  
Hypophysectomized Rats

ABSTRACT The aim of this study was to evaluate the effect of thyroxine (T4) and GH replacement therapy on serum lipoproteins in rats with primary and secondary hypothyroidism and to see whether recovery of GH activity was associated with normalization of serum lipoproteins. In both the primary and secondary hypothyroid rats, total cholesterol (TC) was higher than in normal controls, due to an increase in low-density lipoprotein cholesterol (LDL-c) and to a lesser extent also in high-density lipoprotein cholesterol (HDL-c). Treatment of hypophysectomized rats with GH induced a decrease in the concentration of TC, LDL-c and HDL-c, while liver lipase activity (LLA) increased. The effect of GH on HDL-c was correlated with the increase in LLA. T4 replacement therapy of hypophysectomized rats normalized LDL-c, but HDL-c and LLA were unaffected. During primary hypothyroidism, T4 treatment induced GH activity, increased LLA and reduced the HDL-c concentration. GH treatment of primary hypothyroid rats had a similar influence on the lipid levels and LLA as in hypophysectomized animals, although the lowering of HDL-c was less prominent. These results demonstrate that GH determines serum lipoproteins during both primary and secondary hypothyroidism. Journal of Endocrinology (1990) 125, 403–407

Sign in / Sign up

Export Citation Format

Share Document